To ensure that a patient’s test is billed to their 2024 health benefits, testing must be started before the end of the year. For exome, genome, or Xpanded testing, if you do not expect parental samples to be received before the end of the year, please contact us at support@genedx.com to determine how to proceed.
GeneDx contributes to a wide range of studies and research initiatives. Our team collaborates with top researchers, clinicians and institutions to further progress the field of genetics and genomics.
The GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study offers genomic newborn screening to babies born in 6 New York City hospitals, expanding the number of conditions screened by traditional newborn screening methods. Of the first 4,000 newborns enrolled, 3.7% had positive screenings. The majority of those would not have been picked up by traditional newborn screening today.
Autosomal recessive variants are well-known causes of rare disorders. This study quantified the contribution of these variants to developmental disorders in a large, ancestrally diverse group of patients.
Analysis of over 29,000 neurodevelopmental disorder parent-offspring trios for de novo protein-truncating variants in the nonsense mediated decay escape regions (PTVesc), resulting in identification of 22 candidate Mendelian genes and 22 known Mendelian genes that were not previously known to have PTVesc-associated disease.
GeneDx is committed to ongoing education and training of genetic counseling students. This article illustrates our approach in helping students achieve professional competencies as they relate to roles in laboratory settings.
This conference report of the 8th International RASopathies symposium highlights global perspectives on clinical care and research.
This collaboration across 19 clinical laboratories compared VUS rates across multi-gene panels and exome and genome sequencing. Exome and genome sequencing were found to have higher diagnostic yields and lower VUS rates than gene panels. The study also confirmed that trio testing reduced the number of VUS reported.
In the largest polymicrogyria cohort published to date, a genetic etiology was identified in 32.7% of families, which is more common than previously documented, and 6 genes were newly linked to polymicrogyria.
International experts in primary mitochondrial diseases established gene-disease relationships for Leigh syndrome spectrum across both nuclear and mitochondrial genomes to allow for accurate variant interpretation and diagnosis.
This work utilized a systems-level, multi-omics approach to elucidate the pathogenesis of cerebral arachnoid cysts. The results implicate epigenomic dysregulation due to de novo variants in genes in pathways that regulate transcription and chromatin modification.
This large study of 404 individuals with CTNNB1 variants provides a more comprehensive understanding of CTNNB1-related phenotypes and confirms that cerebral palsy (CP) is a common feature amongst individuals with CTNNB1 variants.
GeneDx’s experience with GeneMatcher highlights our commitment to data sharing, collaborating with our ordering clinicians, and our commitment to helping patients and their families. As a result of GeneMatcher utilization, GeneDx has been involved in the publication of over 200 articles involving novel disease-gene relationships and expanded phenotypes for known disease-causing genes.
Among patients with cerebral palsy who underwent exome sequencing, the prevalence of pathogenic and likely pathogenic variants was 32.7% in a cohort that predominantly consisted of pediatric patients and 10.5% in a cohort that predominantly consisted of adult patients.
Trio exome sequencing (ES) presents a comprehensive method for detection of UPD alongside sequence and copy-number variant analysis.
With the goal of identifying novel genes associated with developmental disorder, this study leveraged over 30,000 parent-offspring exome trios to identify gene-specific enrichments of de novo variants.
Report of the overall diagnostic yield of GeneDx’s first 3,040 exome cases (28.8%). This study identified that analysis of trios significantly improves diagnostic yield compared to proband-only testing for genetically heterogeneous disorders.
